Mechanisms of CD8+ T Cell Apoptosis During Acute and Chronic Viral Infections

急慢性病毒感染过程中CD8 T细胞凋亡机制

基本信息

项目摘要

Project Summary: Our goal is to determine the molecular mechanisms that control contraction of antigenspecific CD8+ T cell responses following acute and chronic viral infections. At the peak of the response, effector CD8+ T cells contain low levels of Bcl-2 and are susceptible to Bim-mediated apoptosis. Activated CD8+ T cells are also susceptible to apoptosis through death receptors such as Fas, Tumor Necrosis Factor Receptor I (TNFRI) or Tumor necrosis factor Related Apoptosis Ligand-Receptor (TRAIL-R). Single mutation of either Bim or any one death receptor results in delayed contraction of antigen-specific CD8+ T cells following acute lymphocytic choriomeningitis virus (LCMV) infection but cell numbers eventually decline. However, loss of both Bim and Fas, a death receptor, results in a lymph node-specific block in contraction following acute LCMV infection. The specific hypothesis that is being addressed in this proposal is that the contraction of antigen-specific CD8+ T cells is controlled by both extrinsic and intrinsic death pathways. Specific Aim 1 will determine the mechanism by which Fas aids Bim in the contraction of antigen-specific CD8+ T cells in the lymph nodes following acute LCMV infection. First, we will determine if the defects in lymph node contraction are T cell autonomous by creating Bim-/-Faslpr/lpr P14 TCR transgenic mice. T cells from these mice will be adoptively transferred into wildtype mice and contraction will be measured. The cells that express Fas Ligand in the lymph node during contraction will be determined by flow cytometry and immunohistochemistry. The importance of expression will be determined by adoptive transfer of mutant P14 transgenic T cells into mice which selectively express functional Fas Ligand. In Specific Aim 2, we will determine the contribution of death receptor and Bim-mediated apoptosis in regulating contraction. This will be accomplished by creating Bimdeficient mice that inducibly express a dominantly interfering FADDdd protein, which blocks death receptor signaling, in their T cells. The sensitivity to apoptosis following exposure to extrinsic and intrinsic deathinducing stimuli will be measured in na¿ve and activated CD8+ T cells from Bim-/-rtTA-FADDdd in vitro. To determine the extent to which loss of all death receptor and Bim-induced apoptosis affects responses in other organs besides the lymph nodes, double mutant mice will be infected with strains of LCMV that induce acute and chronic infection and contraction of antigen-specific CD8+ T cells will be measured in vivo.
项目概述:我们的目标是确定控制抗原特异性收缩的分子机制。 急性和慢性病毒感染后的CD 8 + T细胞反应。在响应的峰值, 效应CD 8 + T细胞含有低水平的Bcl-2,并且对Bim介导的细胞凋亡敏感。激活 CD 8 + T细胞也易于通过死亡受体如Fas、肿瘤坏死因子(TNF)、CD 8 + T细胞受体(CD 8 + T细胞受体)凋亡。 受体I(TNFRI)或肿瘤坏死因子相关凋亡配体-受体(TRAIL-R)。单突变 Bim或任何一种死亡受体导致抗原特异性CD 8 + T细胞在 急性淋巴细胞性脉络丛脑膜炎病毒(LCMV)感染,但细胞数量最终下降。然而,损失 Bim和Fas这两种死亡受体的结合导致淋巴结特异性阻断急性心肌梗死后的收缩。 LCMV感染。本提案所涉及的具体假设是, 抗原特异性CD 8 + T细胞受外在和内在死亡途径控制。具体目标1将 确定Fas辅助Bim收缩抗原特异性CD 8 + T细胞的机制。 急性LCMV感染后的淋巴结。首先,我们将确定淋巴结收缩的缺陷是否 通过建立Bim-/-Faslpr/lpr P14 TCR转基因小鼠,这些小鼠的T细胞将被 过继转移到野生型小鼠中并测量收缩。表达Fas配体的细胞 将通过流式细胞术和免疫组织化学来确定收缩期间淋巴结中的细胞因子。的 表达的重要性将通过将突变P14转基因T细胞过继转移到小鼠中来确定 其选择性表达功能性Fas配体。在具体目标2中,我们将确定死亡的贡献 受体和Bim介导的细胞凋亡调节收缩。这将通过创建Bimdeficient来实现 诱导表达显性干扰FADDdd蛋白的小鼠,该蛋白阻断死亡受体 在他们的T细胞中。外源性和内源性死亡诱导剂对细胞凋亡的敏感性 将在来自Bim-/-rtTA-FADDdd的初始和活化的CD 8 + T细胞中体外测量刺激。到 确定所有死亡受体的丧失和Bim诱导的细胞凋亡影响其他细胞应答的程度。 在淋巴结以外的器官中,双突变小鼠将感染LCMV株, 并且将在体内测量抗原特异性CD 8 + T细胞的慢性感染和收缩。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JASON Mitchell GRAYSON其他文献

JASON Mitchell GRAYSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JASON Mitchell GRAYSON', 18)}}的其他基金

Repurposed Drugs to Inhibit Human T Cells and Autoimmunity
重新利用药物抑制人类 T 细胞和自身免疫
  • 批准号:
    8889627
  • 财政年份:
    2014
  • 资助金额:
    $ 37万
  • 项目类别:
Repurposed Drugs to Inhibit Human T Cells and Autoimmunity
重新利用药物抑制人类 T 细胞和自身免疫
  • 批准号:
    8771735
  • 财政年份:
    2014
  • 资助金额:
    $ 37万
  • 项目类别:
Interferon Alpha Regulation of Murine Gammaherpesvirus Latency
干扰素α对鼠丙型疱疹病毒潜伏期的调节
  • 批准号:
    8648978
  • 财政年份:
    2011
  • 资助金额:
    $ 37万
  • 项目类别:
Redox control of CD8 T cell proliferation, differentiation and death
氧化还原控制 CD8 T 细胞增殖、分化和死亡
  • 批准号:
    8240546
  • 财政年份:
    2008
  • 资助金额:
    $ 37万
  • 项目类别:
Redox control of CD8 T cell proliferation, differentiation and death
氧化还原控制 CD8 T 细胞增殖、分化和死亡
  • 批准号:
    7556319
  • 财政年份:
    2008
  • 资助金额:
    $ 37万
  • 项目类别:
Redox control of CD8 T cell proliferation, differentiation and death
氧化还原控制 CD8 T 细胞增殖、分化和死亡
  • 批准号:
    7783793
  • 财政年份:
    2008
  • 资助金额:
    $ 37万
  • 项目类别:
Redox control of CD8 T cell proliferation, differentiation and death
氧化还原控制 CD8 T 细胞增殖、分化和死亡
  • 批准号:
    7464853
  • 财政年份:
    2008
  • 资助金额:
    $ 37万
  • 项目类别:
Redox control of CD8 T cell proliferation, differentiation and death
氧化还原控制 CD8 T 细胞增殖、分化和死亡
  • 批准号:
    8034740
  • 财政年份:
    2008
  • 资助金额:
    $ 37万
  • 项目类别:
GENE EXPRESSION IN ANTIGEN SPECIFIC LYMPHOCYTES DURING V
V 期间抗原特异性淋巴细胞的基因表达
  • 批准号:
    6372894
  • 财政年份:
    2001
  • 资助金额:
    $ 37万
  • 项目类别:
GENE EXPRESSION IN ANTIGEN SPECIFIC LYMPHOCYTES DURING V
V 期间抗原特异性淋巴细胞的基因表达
  • 批准号:
    6169102
  • 财政年份:
    2000
  • 资助金额:
    $ 37万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了